Literature DB >> 16572310

Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.

F S Taccone1, H Rodriguez-Villalobos, D De Backer, V De Moor, J Deviere, J-L Vincent, F Jacobs.   

Abstract

Reported here is the case of a patient with septic shock due to multidrug-resistant Acinetobacter baumannii, which developed after complicated acute pancreatitis with intra-abdominal abscess. Treatment with colistin methanesulphonate and high doses of meropenem were initiated, but since shock persisted, tigecycline was added to the regimen, resulting in successful resolution of the infection.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16572310     DOI： 10.1007/s10096-006-0123-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  11 in total

1.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 2.  The need for new antibiotics.

Authors:  D M Livermore
Journal:  Clin Microbiol Infect       Date:  2004-11       Impact factor: 8.067

Review 3.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Authors:  Matthew E Falagas; Sofia K Kasiakou
Journal:  Clin Infect Dis       Date:  2005-03-22       Impact factor: 9.079

Review 4.  Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.

Authors:  Mark W Garrison; Joshua J Neumiller; Stephen M Setter
Journal:  Clin Ther       Date:  2005-01       Impact factor: 3.393

5.  Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.

Authors:  María Eugenia Pachón-Ibáñez; Manuel Enrique Jiménez-Mejías; Cristina Pichardo; Ana Cristina Llanos; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

Authors:  Caroline J Henwood; Tess Gatward; Marina Warner; Dorothy James; Mark W Stockdale; Richard P Spence; Kevin J Towner; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

7.  In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Authors:  P J Petersen; N V Jacobus; W J Weiss; P E Sum; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.

Authors:  Carmen Betriu; Iciar Rodríguez-Avial; Blas Ali Sánchez; María Gómez; Juan Alvarez; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.

Authors:  Simona Bratu; Pooja Tolaney; Usha Karumudi; John Quale; Mohamad Mooty; Satyen Nichani; David Landman
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

10.  Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan.

Authors:  Lu-Cheng Kuo; Lee-Jene Teng; Chong-Jen Yu; Shen-Wu Ho; Po-Ren Hsueh
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948
View more
  29 in total

Review 1.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

2.  In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods.

Authors:  Thean Yen Tan; Tze Peng Lim; Winnie Hui Ling Lee; Suranthran Sasikala; Li Yang Hsu; Andrea Lay-Hoon Kwa
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

3.  Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.

Authors:  Michael J McConnell; Juan Domínguez-Herrera; Younes Smani; Rafael López-Rojas; Fernando Docobo-Pérez; Jerónimo Pachón
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 4.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

5.  In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.

Authors:  Luis A Arroyo; Ingeborg Mateos; Verónica González; Javier Aznar
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide.

Authors:  Meritxell García-Quintanilla; Marina R Pulido; Patricia Moreno-Martínez; Reyes Martín-Peña; Rafael López-Rojas; Jerónimo Pachón; Michael J McConnell
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

7.  Acute necrotizing pancreatitis: can tigecycline be included in a therapeutic strategy?

Authors:  S Occhionorelli; L Morganti; R Cultrera; D Andreotti; S Maccatrozzo; L Cappellari; R Stano; G Vasquez
Journal:  G Chir       Date:  2015 Jan-Feb

8. 

Authors:  J Solera; G Jarava
Journal:  Medicine (Madr)       Date:  2009-01-06

9.  Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37.

Authors:  Jennifer H Moffatt; Marina Harper; Ashley Mansell; Bethany Crane; Timothy C Fitzsimons; Roger L Nation; Jian Li; Ben Adler; John D Boyce
Journal:  Infect Immun       Date:  2012-12-17       Impact factor: 3.441

10.  An Amphipathic Undecapeptide with All d-Amino Acids Shows Promising Activity against Colistin-Resistant Strains of Acinetobacter baumannii and a Dual Mode of Action.

Authors:  Alberto Oddo; Thomas T Thomsen; Susanne Kjelstrup; Ciara Gorey; Henrik Franzyk; Niels Frimodt-Møller; Anders Løbner-Olesen; Paul R Hansen
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.